Cidara Therapeutics (CDTX) AI Stock Analysis

• Market Cap: $1.70B
• Dividend Yield: N/A
• Average Volume (3M): 509.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.50
• Revenue Growth: -100.00%
• EPS Growth: 55.31%
• Country: US
• Employees: 38
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -1.65
• Shares Outstanding: 25,358,051
• 10 Day Avg. Volume: 531,057
• 30 Day Avg. Volume: 509,313
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.14
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -2.67
• Enterprise Value/Ebitda: -1.96
• 1Y Price Target: $74.00
• Price Target Upside: 13.17% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 58 Neutral
• Price Target: $66.00 ▲(0.93% Upside)

Cidara Therapeutics' overall stock score is primarily influenced by its challenging financial performance, which is offset by strong technical momentum and positive earnings call sentiment. The company's recent corporate events and promising clinical trial results provide a supportive backdrop, but the lack of profitability and reliance on external financing remain significant concerns.

Positive Factors

Clinical Trial Success

Cidara announced positive topline results from its Phase 2b trial, NAVIGATE, evaluating CD388.

Financial Health

The company ended the quarter with $516.9 million in cash, which is inclusive of a recent financing with gross proceeds of $402 million.

Regulatory Progress

The upcoming end-of-Phase 2 meeting with the FDA is anticipated to provide the green light for initiating the Phase 3 pivotal program.

Negative Factors

Market Dependence

The readout will be a binary catalyst for the stock and is biased toward a positive outcome.

Risk Perception

A statistically significant risk reduction in the 45-55% range would provide significant upside to current levels or CDTX shares re-rating in the $31-36 range.

Cidara Therapeutics Business Overview & Revenue Model

Company Description

Cidara Therapeutics (CDTX) is a biotechnology company focused on the development of novel therapeutics for the treatment of fungal infections and other serious diseases. The company operates primarily in the biotechnology sector, leveraging its innovative platform to design and develop new medicines that address unmet medical needs. Cidara's core products include its lead candidate, rezafungin, an antifungal agent aimed at treating invasive fungal infections, and its Cloudbreak platform, which is designed for the development of combination therapies.

How the Company Makes Money

Cidara Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company likely makes money through milestone payments from partnerships with larger pharmaceutical companies, licensing agreements, and potential royalties from product sales once their therapies are approved and marketed. Significant partnerships with established pharmaceutical firms for co-development or distribution of its products can also contribute to revenue, along with government grants and funding aimed at supporting research and development efforts.

Cidara Therapeutics Financial Statement Overview

Summary

Cidara Therapeutics faces significant financial challenges with persistent losses and negative cash flows. The company has a deeply negative net profit margin and relies heavily on external financing to sustain operations. Despite a low debt-to-equity ratio, the financial trajectory suggests a need for strategic improvements.

Income Statement

Cidara Therapeutics has experienced a significant revenue decline in the latest year, with a revenue growth rate of -98% from the previous year. The net profit margin is deeply negative, at -13362.04% for 2024, indicating substantial losses relative to revenue. The gross profit margin is also negative, suggesting that the company is selling below cost. While biotechnology companies often face high R&D expenses, the magnitude of losses is concerning.

Balance Sheet

The company's debt-to-equity ratio is low due to a relatively high stockholders' equity, indicating low leverage. However, the equity ratio is 76.02%, reflecting a stable capital structure. Despite this, the company has historically negative equity, raising concerns about sustainable financial health. The increase in cash reserves provides some liquidity cushion.

Cash Flow

Operating cash flow is significantly negative, although there has been substantial cash inflow from financing activities. Free cash flow remains negative, and the operating cash flow to net income ratio is negative, due to both operating cash flow and net income being negative. The company is heavily dependent on external financing to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	1.27M	63.91M	64.29M	49.57M	12.07M
Gross Profit	-90.78M	-83.61M	62.38M	64.14M	49.38M	-55.95M
EBITDA	-124.06M	-176.10M	-24.36M	-33.36M	-42.26M	-71.56M
Net Income	-91.32M	-169.83M	-22.93M	-33.58M	-42.47M	-72.37M
Balance Sheet
Total Assets	534.33M	214.80M	67.03M	47.59M	75.33M	60.42M
Cash, Cash Equivalents and Short-Term Investments	510.57M	189.82M	35.78M	32.73M	62.27M	35.91M
Total Debt	2.33M	3.58M	4.88M	1.21M	5.06M	7.96M
Total Liabilities	33.15M	51.49M	75.24M	50.50M	53.75M	49.71M
Stockholders Equity	501.17M	163.31M	-8.21M	-2.90M	21.57M	10.71M
Cash Flow
Free Cash Flow	-129.13M	-176.66M	-22.94M	-28.59M	-25.27M	-54.60M
Operating Cash Flow	-129.02M	-176.53M	-22.43M	-28.47M	-25.23M	-54.41M
Investing Cash Flow	79.00K	-129.00K	-505.00K	-118.00K	-41.00K	-186.00K
Financing Cash Flow	481.49M	337.06M	25.98M	-951.00K	44.60M	37.28M

Cidara Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 65.39
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CDTX, the sentiment is Positive. The current price of 65.39 is above the 20-day moving average (MA) of 63.61, above the 50-day MA of 55.81, and above the 200-day MA of 29.95, indicating a bullish trend. The MACD of 2.85 indicates Positive momentum. The RSI at 59.32 is Neutral, neither overbought nor oversold. The STOCH value of 59.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CDTX.

Cidara Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDTX	58 Neutral	$1.70B	―	-37.05%	―	-100.00%	55.31%
FHTX	52 Neutral	$312.61M	―	322.49%	―	-31.30%	36.26%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
ITOS	49 Neutral	$447.80M	―	-34.97%	―	-100.00%	-61.86%
OCGN	47 Neutral	$324.80M	―	-569.99%	―	33.39%	-7.11%
CRVS	41 Neutral	$412.81M	―	-68.67%	―	―	-50.83%
TVGN	33 Underperform	$181.17M	―	-124.74%	―	―	-406.67%

Cidara Therapeutics Corporate Events

Cidara Therapeutics Announces $350 Million Stock Offering

On June 24, 2025, Cidara Therapeutics announced an agreement with several underwriters to sell approximately 7.95 million shares of its common stock at $44.00 per share in a public offering, aiming to raise around $350 million. The offering, scheduled to close on June 26, 2025, marks a significant financial move for Cidara, potentially enhancing its market position and providing capital to advance its therapeutic developments.

Cidara Therapeutics Suspends ATM Prospectus with Jefferies

On June 24, 2025, Cidara Therapeutics announced the suspension and termination of its ATM Prospectus related to common stock sales under its agreement with Jefferies LLC. The company will halt stock sales until a new prospectus is filed, though the sales agreement itself remains active, indicating a strategic pause rather than a complete cessation of stock activities.

Cidara Therapeutics Reports Positive Phase 2b Trial Results

On June 23, 2025, Cidara Therapeutics announced positive results from its Phase 2b NAVIGATE trial for CD388, a drug aimed at preventing seasonal influenza. The trial demonstrated statistically significant prevention efficacy across all dose groups, with CD388 being well-tolerated and showing no unexpected adverse events. These results could enhance Cidara’s positioning in the antiviral market, and the company has submitted a meeting request to the FDA to discuss the Phase 3 trial design.

Cidara Therapeutics Approves Key Amendments at Annual Meeting

On June 18, 2025, Cidara Therapeutics held its Annual Meeting of Stockholders, where key amendments were approved. The stockholders agreed to increase the number of shares authorized under the 2024 Equity Incentive Plan by 2,880,000 shares and doubled the authorized shares of common stock from 50 million to 100 million. These changes are expected to enhance the company’s operational flexibility and support its growth strategy. Additionally, the election of directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, were confirmed.